The fund, established by the Eli Lilly and Company Foundation, Lumina Foundation and Central Indiana Community Foundation, will focus on solutions that address racial inequities in the criminal justice system INDIANAPOLIS , June 25, 2020 /PRNewswire/ -- A coalition of local stakeholders has

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and

RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ® (empagliflozin) in

INDIANAPOLIS , June 17, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine.

- Data showed approximately 1 in 3 people diagnosed with migraine take a recommended acute prescription medication for a migraine attack, while less than 1 in 5 who suffer frequent migraine attacks take a recommended preventive prescription medication   - OVERCOME (Observational Survey of the

monarchE demonstrates positive results in Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence   Verzenio given with standard endocrine therapy showed improvement compared to standard endocrine therapy alone   Verzenio is the only CDK4 & 6 inhibitor to demonstrate

INDIANAPOLIS , June 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Lyumjev ™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's (NYSE: LLY) new rapid-acting insulin indicated to improve glycemic control in adults with type 1

- Study Will Further Understanding of Baricitinib's Potential as a COVID-19 Treatment   - Data Will Complement Ongoing NIAID Trial and Investigator-Initiated Trials INDIANAPOLIS , June 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been

INDIANAPOLIS , June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity ® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA)

Eli Lilly and Company commits 25,000 employee volunteer hours of service to help speed progress INDIANAPOLIS , June 13, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the